Protein Therapeutics for Junctional Epidermolysis Bullosa: Incorporation of Recombinant β3 Chain into Laminin 332 in β3-/- Keratinocytes In Vitro  by Igoucheva, Olga et al.
Protein Therapeutics for Junctional Epidermolysis
Bullosa: Incorporation of Recombinant b3 Chain
into Laminin 332 in b3/ Keratinocytes In Vitro
Olga Igoucheva1, Aislinn Kelly1, Jouni Uitto1 and Vitali Alexeev1
Junctional epidermolysis bullosa (JEB) is an inherited mechanobullous disease characterized by reduced
adherence of the epidermal keratinocytes to the underlying dermis, and is often caused by the absence of
functional laminin 332 due to the lack or dysfunction of its b3 chain. As there are no specific therapies for JEB,
we tested whether a protein replacement strategy could be applicable for the restoration of the laminin 332
assembly and reversion of the JEB phenotype in human keratinocytes that lack b3 subunit. Here, we developed
the protocol for production and purification of the biologically active recombinant b3 chain. Next, we
demonstrated that delivery of recombinant b3 polypeptide into the endoplasmic reticulum of the immortalized
b3-null keratinocytes led to the restoration of the laminin 332 assembly, secretion, and deposition into the
basement membrane zone, as confirmed by Western blot analysis, confocal immunofluorescent microscopy
in vitro, and on cultured organotypic human JEB skin reconstructs. Although the amount of laminin 332
produced by protein-treated b3-null keratinocytes is lower than that in normal human keratinocytes, our results
demonstrate the applicability of the recombinant proteins for JEB treatment and open new perspectives for the
development of novel therapeutics for this inherited, currently intractable, skin disorder.
Journal of Investigative Dermatology (2008) 128, 1476–1486; doi:10.1038/sj.jid.5701197; published online 13 December 2007
INTRODUCTION
Inherited epidermolysis bullosa (EB) is a group of mechan-
obullous disorders characterized by the development of
blisters following minor trauma to the skin (Fine et al., 2000).
Traditionally, EB is divided into three major categories:
simplex, junctional, and dystrophic, with at least 20 distinct
clinical phenotypes. All forms of inherited EB result from
mutations in the genes that encode structural proteins,
which normally reside within the epidermis, dermal–epider-
mal junction, or the upper papillary dermis (Fine et al., 2000).
In the most severe junctional form of EB (JEB), the Herlitz
variant (H-JEB), skin separation occurs at the level of lamina
lucida of the cutaneous basement membrane zone (BMZ).
This form of EB is frequently lethal during the early post-natal
period. Immunohistochemical analysis of the skin of affected
infants has shown reduced or absent staining for laminin 332
(laminin 332 was previously known as laminin 5; for recently
modified nomenclature of laminins, see Aumailley et al.,
2005), suggesting an important role for this protein in
adhesion of basal keratinocytes to the basal lamina. Laminin
332 is composed of three distinct polypeptides, a3, b3, and
g2, which form a heterotrimer with a distinctive cross-shaped
structure (Engel, 1992). Recent data suggest that assembly
of the trimeric laminin proceeds from the formation of the
b3g2 heterodimer to the a3b3g2 heterotrimer (Matsui et al.,
1995a, 1998) within rough endoplasmic reticulum (rER).
Subsequently, trimeric laminin 332 is secreted from the
keratinocytes and interacts with hemidesmosomal a6b4
integrin and the amino-terminal NC-1 domain of the type
VII collagen, thus providing a firm attachment of keratino-
cytes to dermal anchoring fibrils (Chen et al., 1997;
Brittingham et al., 2006). Therefore, the ablation of any
subunit of laminin 332 results in separation of the epidermis
from the dermis, as found in H-JEB.
Three distinctive genes, LAMA3, LAMB3, and LAMC2,
encode the a3, b3, and g2 chains of laminin 332, respec-
tively. Mutational analysis of these genes has revealed that in
most cases H-JEB is caused by premature stop codons in both
alleles of any of the three laminin 332 genes. In less severe,
type XVII collagen-independent, non-Herlitz variants of JEB
with reduced laminin 332 expression, mutations in genes
encoding laminin 332 polypeptides have been characterized
mostly as missense or in-frame splice mutations (Varki et al.,
2006). These mutations do not cause the entire absence of
individual polypeptides and apparently do not interfere with
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the assembly of the trimeric molecule, but rather disturb the
function of the laminin 332, resulting in milder, non-lethal
JEB phenotypes.
At present, there are no specific therapies for any form of
hereditary JEB. Advances in gene therapy hold much promise
for the development of the gene-based molecular therapies of
this inherited disorder (Mavilio et al., 2006; Featherstone and
Uitto, 2007). However, current gene therapy approaches are
not readily applicable for the treatment of patients with JEB,
and the day-to-day management of the disease continues to
revolve around prevention of mechanical trauma and infec-
tion. Therefore, the search for new alternative approaches is
warranted.
In recent years, recombinant proteins have emerged as a
new class of molecular therapeutics. Recombinant proteins
and polypeptides have been successfully used in the treat-
ment of a number of human diseases (Krejsa et al., 2006).
Recently, Woodley et al. (2004) demonstrated the potential
of protein application for treatment of cutaneous disorders,
specifically the dystrophic forms of EB, where skin separation
below the lamina densa is caused by mutations in the
COL7A1 gene (Varki et al., 2007). In their study, human
recombinant type VII collagen, injected intradermally into
immunodeficient or immunocompetent mice, was retained
in the BMZ for more than 2 months after a single injection
of the protein. With respect to laminin 332, no studies using
recombinant protein have been reported yet. However,
Robbins et al. (2001b), using a gene profiling approach,
showed that culturing JEB keratinocytes on laminin 332-rich
extracellular matrix (ECM) restored the expression of many
of the genes downregulated in JEB.
In this study, we extend the applicability of the protein
therapy approach to a new group of blistering diseases, the
junctional forms of EB, and demonstrate that treatment of the
H-JEB keratinocytes with recombinant b3 chain restores the
formation and functional activity of the trimeric laminin 332.
RESULTS
Expression vectors and protein production
To verify the expression of the full-length b3 subunit from
pcDNA-LAMB3 expression vector, 2 mg of the plasmid was
transfected into H-JEB keratinocytes using FuGene6 transfec-
tion reagent. The expression and secretion of the full-length
b3 chain (140 kDa polypeptide) was confirmed by Western
blot analysis using anti-b3-specific antibodies (Figure 1a).
For the in vitro production of the recombinant protein, the
FreeStyle 293 Mammalian Expression System was used. This
system allows large-scale protein production and mammalian
post-translational modifications of the expressed proteins,
important for the therapeutic applications. To investigate
whether this expression system is suitable for the production
of the recombinant b3 chain of laminin 332, the efficacy of
plasmid DNA delivery into 293F cells was compared bet-
ween liposome-based 293Fectin transfection reagent, pro-
vided as a part of the FreeStyle protein expression system,
and electroporation-based Amaxa nucleofection. Side-
by-side comparison clearly demonstrated that nucleofection
of plasmid DNA resulted in at least 10 times higher DNA
delivery than 293Fectin-based transfection (Figure 1b and c).
To determine which method of DNA delivery yields higher
expression and secretion of the recombinant b3 polypeptide,
culture media from pcDNA-LAMB3-transfected/nucleofected
293F cells (1106 cells per reaction) were collected at
different time points (24, 48, and 72 hours after transfection/
nucleofection), concentrated, and analyzed by Western
blotting for the presence of the secreted b3 subunit. As
shown in Figure 1, nucleofection resulted in a higher secre-
tion of the recombinant protein into the culture medium
during the first 24 hours, when compared with 293Fectin-
mediated transfection (Figure 1d and e). Remarkably, trun-
cated and degraded proteins of the lower molecular weight
were almost undetectable in the culture media collected from
the nucleofected cells, and secretion of the b3 polypeptide
remained high during an additional 2 days of culture. Based
on these findings, nucleofection was adopted as a primary
DNA delivery method for the medium-scale production of
the recombinant protein.
Medium-scale protein purification
To generate sufficient amount of the recombinant protein,
80 concurrent nucleofection reactions were performed. 293F
cells nucleofected with the pcDNA-LAMB3 plasmid were
cultured to obtain 3.2 L of culture media, which was concen-
trated and analyzed for the protein content by SDS-PAGE.
Since no contaminating proteins in the range of ±50 kDa
from the b3 polypeptide were detected (Figure 2a), the
recombinant b3 was further purified by one-step gel-filtration
chromatography using a fast performance liquid chromato-
graphy system. After multiple rounds of gel filtration, recom-
binant b3-containing fractions were combined, and an
aliquot was analyzed by SDS-PAGE and Western blotting.
As shown in Figure 2, no contaminating proteins or degrada-
tion of the b3 chain could be detected in this fraction. Based
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Figure 1. Laminin b3 expression and secretion. (a) Expression and secretion
of the laminin b3 from the pcDNA-LAMB3 after transient transfection into
H-JEB keratinocytes. Arrows on the left point to positions of molecular
weight markers, arrows in the middle point to the b3 subunit. (b and c) GFP
expression in 293F cells after transient transfection using (b) 293Fectin
transfection reagent or (c) Amaxa-based nucleofection. (d and e) Western
blot analysis of the recombinant b3 chain secretion into culture media after
(d) transient transfection or (e) nucleofection at various time points. Lane 1:
48 hours, mock transfected 293F cells. Lanes 2, 3, and 4: 24, 48, and 72hours
after pcDNA-LAMB3 transfection/nucleofection, respectively. For the
analysis of proteins by Western blotting, 5 mg of total protein from cell lysates
and 15 ml of culture media per lane were loaded. GFP, green fluorescent
protein.
www.jidonline.org 1477
O Igoucheva et al.
Protein Therapy for JEB
on the protein concentration measurements by colorimetric
assay and by absorbance at 280 nm, we were able to obtain
approximately 50 mg of pure protein from 3.2 L of culture
media.
Protein delivery in vitro
After having achieved a relatively high yield and purity of the
recombinant b3 chain of laminin 332, the in vitro protein
delivery to normal human (NHKs) and immortalized H-JEB
keratinocytes was optimized using b-galactosidase reporter
protein and ProJect protein transfection reagent. Under the
optimized conditions, transfection of 4 mg of the recombinant
protein per 5 105 initial ‘‘target’’ cells resulted in a highest
efficacy of protein delivery, approaching 85% in both H-JEB
and NHK cells (Figure 2b–e).
Transfection of the recombinant b3 chain and restoration of the
laminin 332 assembly
To determine whether recombinant protein can contribute to
the assembly of the mature laminin 332, purified b3 subunit
was transfected under optimized conditions into H-JEB
keratinocytes. In all experiments, untreated H-JEB cells and
NHK were used as negative and positive controls, respec-
tively. After transfection, re-plating, and additional 18 hours
of culture, protein samples from cell lysates and correspond-
ing culture media were prepared in native and denaturing
conditions for Western blot analysis. Under both conditions,
recombinant b3 polypeptide and chimeric laminin 332 that
comprised of endogenous a3 and g2 and recombinant b3
chains were detected in cell lysates and culture media of
the protein-treated cells using b3-specific and laminin 332
conformation-specific GB3 antibodies, respectively (Figure
3a and b). Neither one of the proteins were detected in
untreated H-JEB keratinocytes. Laminin 332 was assembled
as 460 kDa protein and secreted to the culture media, where
it was detected as processed 440 kDa protein (Figure 3b). The
presence of individual a3, b3, and g2 chains in the assembled
chimeric protein was confirmed by Western blot analysis
using chain-specific antibodies (Figure 3c). The extent of the
laminin 332 formation and secretion in b3-treated H-JEB cells
was lower than that in NHK, suggesting that even the excess
of the recombinant protein cannot fully restore trimeric
protein assembly.
Indirect immunofluorescent and confocal microscopy analyses
To confirm our findings at the cellular level, we analyzed the
presence of the ProJect-delivered b3 chain in treated
keratinocytes. As shown in Figure 3, in protein-transfected
cultures approximately 65% of the cells contained b3 subunit
in the cytoplasm in the perinuclear area, presumably in
association with rER (Figure 3d). Also, using GB3 antibodies,
we confirmed the formation and deposition of the trimeric
laminin 332 onto the plastic substrata from protein-treated
H-JEB keratinocytes. Consistent with our Western blot analysis,
the amount of the deposited laminin 332 was significantly
lower than that from normal keratinocytes (Figure 3c).
Collectively, these data suggest that recombinant b3 chains
contribute to the formation of mature laminin 332.
The intracellular delivery of the recombinant b3 chain and
the formation of laminin 332 in protein-treated H-JEB
keratinocytes were additionally confirmed by confocal
microscopy. To determine whether the transfected protein
can be delivered into the rER, where trimeric laminin is
assembled (Nishiyama et al., 2000), we performed an indirect
immunofluorescent detection of the b3 chain, laminin 332,
and rER in protein-treated cells. Many of the protein–ProJect
complexes formed large aggregates that did not penetrate the
membranes of the cellular organelles (Figure 4a). Never-
theless, similar to endogenously produced b3 chain in normal
keratinocytes (Figure 4n), recombinant b3 was detected in the
majority of protein-treated cells in colocalization with rER
(Figure 4c and e). However, contrary to normal keratinocytes
where trimeric laminin 332 was robustly colocalized with
rER (Figure 4o and r), in b3-treated cells only a small amount
of the trimeric protein was associated with rER (Figure 4g, h,
and k). The majority of the chimeric laminin 332 was evenly
distributed in the cytoplasm and polarized toward the base
of the cells (Figure 4i–k). Moreover, it was organized in
string-like structures that were radially extended from the
nucleus to the periphery of the cells (Figure 4i). Such intra-
cellular organization was not detected in normal keratino-
cytes (Figure 4o and r). When detected on plastic substrata,
trimeric laminin 332 was widely spread over the tissue
culture plate both in normal and protein-treated cells (Figure
4l and r, respectively). Although the extent of substrata-asso-
ciated fluorescence in b3-treated cells was lower than that in
normal keratinocytes, these observations suggest that even a
few protein-treated cells can secrete sufficient amounts of
laminin 332 to restore the attachment of the neighboring
b3-null keratinocytes.
Collectively, these assays demonstrated that in vitro
produced and purified b3 chain can be efficiently delivered
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Figure 2. Purification and transfection of recombinant proteins. (a) Lane 1:
Concentrated culture media collected from b3-producing 293F cells; lane 2:
fraction containing laminin b3 after gel filtration. Samples of culture media
and purified protein were prepared under denaturing condition, separated
on 4–12% gradient PAGE, and stained with GelCode Blue reagent. Arrows
on the left point to positions of molecular weight markers, and arrow on
the right points to the b3 subunit of laminin 332. (b–e) Delivery of the
recombinant b-galactosidase into (b, d) normal and (c, e) H-JEB keratinocytes.
(b and c) Photographs of protein-transfected wells stained for the
b-galactosidase activity; (d and e) magnified fields of (b and c), respectively.
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into the b3-null keratinocytes and interact with endogenous
a3 and g2 chains to assemble mature laminin 332, which can
be secreted from the keratinocytes and deposited onto plastic
substrata.
Substrata binding and adhesion
As it has been shown previously (Vailly et al., 1998), resto-
ration of the laminin b3 expression in H-JEB keratinocytes by
gene transfer re-establishes keratinocytes attachment to the
plastic substrata in vitro. To test whether protein treatment
also restores the attachment, b3-treated H-JEB keratinocytes
were subjected to the substrata-binding assay. At a relative
centrifugal force of 500 g, only 14% of NHKs were dislodged,
while 62% of the H-JEB cells lost attachment under similar
conditions (Figure 5a). However, the substrata-binding
strength of the H-JEB cells after treatment was substantially
increased, as indicated by lower number (32%) of detached
cells after centrifugation (Figure 5a). These results clearly
indicate that treatment of the H-JEB keratinocyte with the
recombinant b3 subunit results in markedly increased
adhesion of the protein-treated cells.
To determine whether the ECM secreted by protein-treated
H-JEB keratinocytes can support cell adhesion, we utilized a
modified adhesion assay (Carter et al., 1990). As shown in
Figure 5, during the first 2 hours after plating, only a few of
the H-JEB keratinocytes were attached to matrices secreted by
untreated H-JEB cells as reflected by almost complete
absence of crystal violet-stained cells. At the same time,
as calculated from the absorption values of crystal violet
staining, approximately 20 and 40 times more keratinocytes
were attached to matrices secreted by protein-treated
(H-JEBþ b3) and wild-type keratinocytes (NHK), respectively
(Figure 5b). After 12 hours of incubation, the differences in
the attachment of H-JEB cells to these matrices became more
obvious. Based on the absorption values, H-JEB keratinocytes
attached 10 and 13.5 times more efficiently to the matrices
produced by b3-transfected and normal keratinocytes, than to
the matrices secreted by H-JEB cells (Figure 5b). These
findings correlate with the data obtained in substrata binding
assay and directly point to the functionality of the chimeric
laminin 332 in restoring adhesive properties of H-JEB
keratinocytes.
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Figure 3. Western blot and immunofluorescent analyses of the laminin b3 intracellular delivery and formation of the chimeric laminin 332. (a) Analysis
of laminin b3 delivery and secretion. Lanes 1 and 2: Cell lysates; lanes 3 and 4, culture media collected from H-JEB and b3-treated H-JEB keratinocytes,
respectively. Protein samples were prepared under denaturing conditions and detected on blots by laminin b3-specific antibodies. Arrow on the right
points to b3 subunit. (b) Western blot analysis of assembly and secretion of laminin 332. Lanes 1 and 2: Lysates and culture media collected from NHKs,
respectively; lanes 3 and 4: lysates of H-JEB and b3-treated H-JEB keratinocytes, respectively; lanes 5 and 6: culture media from H-JEB and b3-treated
H-JEB keratinocytes, respectively. Protein samples were prepared in native conditions, separated on 4% PAGE, and detected by laminin 332-specific (GB3)
antibodies. Arrows on the right point to unprocessed and processed trimeric laminin 332 (a3b3g2). (c) Western blot analysis of individual chains of laminin 332
in the trimeric protein, immunoprecipitated with GB3 antibodies from culture media collected from b3-transfected H-JEB keratinocytes. Arrows on the left
point to a3, b3, and g2 chains of laminin 332, detected with protein-specific antibodies, and to IgG (g2*: processed form of the g2 chain). In all panels, arrows
on the left point to positions of the molecular weight markers. (d) Immunofluorescent detection of b3 and laminin 332 (red) in normal (NHK), H-JEB, and
b3-treated H-JEB keratinocytes. Cell types are indicated above the panels, and detected proteins indicated on the right. Nuclei stained with DPAI (blue).
Bar¼100 mm. For the analysis of proteins by Western blotting, 5 mg of total protein from cell lysates and 15 ml of culture media per lane were loaded.
The analysis was performed 18 hours after transfection.
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Restoration of the laminin 332 in human skin organotypic
cultures
To determine whether chimeric laminin 332 comprised of
endogenous a3, g2, and recombinant b3 chains can be
secreted from protein-treated H-JEB cells and deposited into
the BMZ, we established organotypic reconstructs of human
skin. For the reconstruction of the epidermal component of
the skin, NHK, H-JEB, and b3-treated H-JEB keratinocytes
were used. All these cells gave rise to a multilayered epider-
mis, which structurally resembled human skin (data not
shown). Immunofluorescent analysis showed that b3 chain
was present intracellularly in basal keratinocytes of normal
skin and completely absent in H-JEB reconstructs (Figure 6a
and b). Recombinant b3 chain was also detected in a few
of the protein-treated H-JEB keratinocytes (Figure 6c). The
mature trimeric laminin 332 was present extracellularly as
an evenly distributed layer along the BMZ in recons-
tructs of normal skin (Figure 6d) and absent in H-JEB skin
reconstructs (Figure 6e). However, when b3-treated H-JEB
keratinocytes were used for the reconstitution of the epider-
mis, mature laminin 332 was formed, secreted, and deposited
into the BMZ (Figure 6f). Although the staining for laminin
332 was not continuous, trimeric protein was widely distri-
buted throughout the reconstructs. Using AutoQuant imaging
software, we determined that on 50 consecutive cross-
sections of a reconstruct that comprised b3-treated H-JEB
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Figure 4. Confocal immunofluorescent microscopy. (a–e) Coimmunofluorescent detection of rER (red) and b3 subunit (green) in b3-transfected H-JEB
keratinocytes; (f–l) coimmunofluorescent detection of rER (red) and laminin 332 in protein-treated cells. (a) Aggregates of b3–ProJect complexes and
colocalization of b3 and rER; (b) Z-stack of the consecutive Z-slices of cells in panel a; (c) rER in untransfected H-JEB keratinocytes and colocalization of
b3 subunit and rER; (d) Z-stack of the consecutive Z-slices of cells in panel c; (e) colocalization of b3 and rER lumen and tubules; (f–j) consecutive Z-slices of a
H-JEB keratinocytes transfected with recombinant b3 subunit. (k) Z-stack of the consecutive Z-slices of cells in panels f–j. (l) Deposition of laminin 332 from
b3-treated keratinocytes. (n) Colocalization of b3 subunit and ER in NHK; (o and r) colocalization of laminin 332 and ER in NHK and deposition of the
trimeric protein. (a–e and n) Green arrowheads, laminin b3; yellow arrowheads, colocalization of the b3 subunit and ER; red arrowheads, rER in untransfected
H-JEB cells. (f–k) Green arrowheads, laminin 332; yellow arrowheads, colocalization of laminin 332 and ER; red arrowheads, ER in untransfected H-JEB
cells. (l, m, o, and r) Green arrowheads with asterisk, secreted and deposited on plastic substrata laminin 332. Bar¼20 mm.
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keratinocytes (approximately 0.351.2mm area, 1/200 of
total reconstruct area), the largest gap between patches of
laminin 332 was approximately 0.26 0.32mm. The intensity
of the AlexaFluor488 fluorescence that labels laminin 332 at
the BMZ accounted for 54% of that measured on the cross-
sections of a normal human skin reconstruct (Figure 5b).
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Figure 5. Substrata binding and adhesion assays, and analysis of the BMZ-associated laminin 332. (a) Substrata binding assay. Each point is the average of
triplicates from three independent experiments presented as the mean±SD of detached cells. NHK, normal human keratinocytes; H-JEB, b3-null keratinocytes;
H-JEBþb3, protein-treated keratinocytes. (b) Cell adhesion assay. Each point is the average of triplicates from three independent experiments presented as the
mean±SD of absorbance at OD A280. H-JEB cells were seeded onto wells coated with ECM produced by NHKs, b3-null keratinocytes (H-JEB), and protein-
treated H-JEB keratinocytes (H-JEBþ b3). Cells were allowed to attach for 2 or 12 hours, as indicated below the panel. (c) Quantitative, fluorescence-based
analysis of the BMZ-associated laminin 332 in skin organotypic cultures comprised of NHKs, H-JEB keratinocytes (H-JEB), or b3-treated keratinocytes
(H-JEBþ b3). Values are mean±SD of the BMZ-associated fluorescence relative to total fluorescence (100%) of the analyzed fields.
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Figure 6. Organotypic cultures of normal, H-JEB, and b3-treated H-JEB human skin. (a–l) Representative sections of human skin organotypic cultures stained for
(a–c) laminin b3, (d–f) laminin 332, (g–i) laminin 332 and a6 integrin, or (j–i) laminin 332 and b4 integrin. Epidermal components of the organotypic cultures
were reconstituted using (a, d, g, j) NHKs, (b, e, h, k) H-JEB keratinocytes (H-JEB), and (c, f, i, l) b3-treated keratinocytes (H-JEBþ b3). Bar¼ 100 mm.
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As functional laminin 332 is important for hemidesmo-
somal formation and stability (Baker et al., 1996), we
examined the effect of protein-based treatment on the
polarization of the a6b4 integrin in human skin reconstructs
after 4 weeks of the in vitro culture. During this extended
culture period, reconstructs comprised of normal and protein-
treated H-JEB keratinocytes showed clear BMZ-associated
staining for the trimeric laminin 332, which was colocalized
with both a6 and b4 integrins at the BMZ. In reconstructs
of H-JEB skin, both a6 and b4 integrins were mislocolized
throughout the epidermis in the absence of the b3 subunit
(Figure 6g–l). Taken together, these observations demonstrate
that deposition of the chimeric laminin 332 into the BMZ is
stable at least for 4 weeks and leads to proper polarization
of both a6 and b4 integrins to the BMZ in protein-treated
skin reconstructs.
DISCUSSION
Our studies demonstrate that the recombinant b3 subunit
of the human laminin 332 can be produced in vitro and used
for the restoration of the trimeric laminin 332 assembly in
immortalized b3-null keratinocytes. Similar to the laminin
332 produced by wild-type keratinocytes, the chimeric
laminin 332 presumably undergoes extracellular maturation
and restores the adhesion of the keratinocytes. Our data
further suggest that recombinant individual chain of laminin
332 can be utilized for the restoration of trimeric laminin and,
potentially, for treatment of JEB and alleviation and preven-
tion of the blister formation associated with this devastating
skin disorder.
During the last two decades, various protein-based thera-
peutics have been developed and implemented into clinical
practice for treatment of metabolic disorders, autoimmune
diseases, and cancer. These therapeutics include drugs that
either supplement (cytokines, growth factors, enzymes) or
block (antibodies, soluble receptors, enzyme inhibitors) the
activities of endogenous proteins. The majority of them are
recombinant proteins that in vivo can present their activities
as monomers, homodimers, or homomultimers. In contrast,
structural proteins, including those involved in the formation
of BMZ, such as collagens and laminins, represent specific
proteins that have to undergo several significant modifica-
tions to become functionally active. For instance, to form
mature laminin 332, all three individual chains of the
protein (a3, b3, and g2) have to go through intracellular
post-translational modifications and assembly into a3/b3/g2
heterotrimer. Furthermore, the trimeric protein has to be
secreted and undergo extracellular processing prior to its
association with type VII collagen and a6b4 integrin (Chen
et al., 1997; Brittingham et al., 2006). The complexity
of these events makes the development of protein-based
therapeutics for the replacement of structural proteins
challenging. However, considering limitations of the current
gene therapy approaches, protein replacement seems to be
an alternative strategy that, if successful, may provide imme-
diate, clinically significant benefits for JEB patients.
Most of the protein therapeutics are produced in mam-
malian cells. Production of recombinant proteins follows a
well-established scheme that includes the following: (1)
transfer of the recombinant DNA coding for a protein of
interest; (2) selection and expansion of protein-expressing
cells; and (3) establishment of individual cell lines with the
highest protein production. Here, utilizing a transient
expression system, rather than stable cell lines for protein
production, we demonstrated that recombinant b3 chain of
laminin 332 can be produced in relatively large quantities
during a short period of time. We also showed that one-step
gel-filtration can be optimized for the purification of the
recombinant b3 chain to minimize protein degradation and
increase the yield of the pure recombinant protein. However,
if protein replacement strategy will show clinical benefits
in upcoming preclinical studies on animal models of JEB
(Kuster et al., 1997; Arin and Roop, 2001; Meng et al., 2003),
alternative approaches for the production of recombinant
chains of laminin 332 can be established. Currently, we are
testing the use of strong mammalian promoters in conjunc-
tion with universal chromatin opening elements and sodium
butyrate (Williams et al., 2005; de Poorter et al., 2007) for the
enhancement of protein production.
A major question regarding protein replacement strategy
for the restoration of laminin 332 is how to achieve effective
delivery of the missing chain into defective keratinocytes in a
manner that will facilitate formation of the trimeric molecule.
Here, we presented evidence that ProJect-mediated transfec-
tion of the H-JEB human keratinocytes in vitro with recombi-
nant b3 chain resulted in the delivery of the protein into the
rER and subsequent formation of the chimeric laminin 332.
Although the precise mechanism of ProJect-mediated protein
delivery into the rER is not known, we suggest that protein–
ProJect complexes fuse with the membranes of this organelle,
releasing protein into the rER. Although we found that
b3–ProJect complexes often formed relatively large aggre-
gates that could not be delivered into the rER, we demon-
strated that ProJect-mediated transfection of b3 subunit into
H-JEB keratinocytes leads to its incorporation into the trimeric
laminin 332. Even so, for future preclinical and clinical
studies, other protein transfection reagents, such as Chariot
(Active Motif, Carlsbad, CA), or cell-penetrating oligoarginine
carriers (Bendifallah et al., 2006) and arginine-grafted
polyamidoamonine dendrimers (Kim et al., 2006) can be
tested.
Using confocal immunofluorescent microscopy, we also
demonstrated that only a small portion of the trimeric laminin
332 in protein-transfected cells was associated with rER. The
majority of the chimeric protein was widely distributed in the
cytoplasm, where it was organized into string-like structures.
These observations suggest that immediately after incorpora-
tion of the recombinant b3 chain, assembled laminin 332
leaves the rER, becomes secreted from the cells, and is
deposited onto a relatively large area of the culture plate.
Wide distribution of the chimeric laminin 332 on plastic
substrate allows us to suggest that even relatively few protein-
treated cells can produce functional laminin 332 in amounts
sufficient to restore the adherence of the neighboring
b3-negative keratinocytes. The data obtained in substrata
binding assay, showing an essential restoration of the binding
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capacity of the H-JEB keratinocytes after protein treatment,
directly support this notion.
To experimentally test whether protein-treated cells are
capable of secreting sufficient amounts of laminin 332
to restore dermal–epidermal junction, we established skin
organotypic cultures. As expected, individual b3 chains were
detected inside basal keratinocytes of normal human skin
reconstructs and were absent in H-JEB organotypic cultures.
More importantly, immunofluorescent analyses of both
normal and protein-treated H-JEB skin reconstructs showed
polarized deposition of trimeric laminin 332 in the BMZ and
proper polarization of the hemidesmosomal a6b4 integrins in
the reconstituted epidermis. Although laminin 332 deposition
was uneven in reconstructs made of protein-treated cells,
those patches were evenly distributed along the dermal–epi-
dermal junction, leaving only small gaps where the protein
was absent. Remarkably, the quantity of the trimeric laminin
produced by b3-treated H-JEB keratinocytes was determined
to be more than 50% of that produced by NHKs during the
same period in parallel reconstructs.
Collectively, our observations suggest two potential strat-
egies of the protein-based therapeutics for JEB treatment/
blister prevention: (1) direct in vivo transfection of the recom-
binant protein into epidermal keratinocytes, and (2) ex vivo
transfection of the recombinant protein into keratinocytes
isolated from JEB patient’s skin and subsequent engraftment
of the protein-treated cells onto the affected areas.
In self-renewing tissues, such as cutaneous epithelia,
clinically useful therapies require sustainable presence of
the therapeutics. Protein replacement strategy presents
certain concerns regarding duration of the therapeutic effect,
which, in general, depends on the stability of the recombi-
nant protein at the therapeutic site. Previous studies showed
that in human skin reconstructs, retrovirus-mediated gene
transfer of the b3-encoding cDNA into H-JEB keratinocytes
resulted in the presence of the restored laminin 332 at the
BMZ for an extended period of time (up to 12 weeks), while
b3-transduced cells were lost from the epidermis within 3–4
weeks (Robbins et al., 2001a). It was suggested that the exten-
ded presence of laminin 332 at the BMZ of the reconstructs is
due to progeny of the transduced cells. However, these data
may also suggest that incorporation of the protein into the
BMZ leads to its stabilization and protection from rapid
degradation by proteases. This notion is also supported by
observations that after single administration, recombinant
human type VII collagen was stably present at the BMZ of
mouse skin during a 2-month follow-up period (Woodley
et al., 2004). Considering our data demonstrating the
presence of the laminin 332 at the BMZ of the protein-
treated H-JEB skin reconstructs for 2–4 weeks, we hypo-
thesize that laminin 332 replacement strategy may have
long-lasting therapeutic effects. However, only in vivo animal
studies, which are currently ongoing in our laboratory, will
allow us to experimentally address the question of duration
of protein replacement and optimize treatment protocols
to achieve durable therapeutic effects.
With further optimization of protein production and
delivery, protein replacement strategies can be developed
toward clinical application for localized treatment of JEB and
other currently intractable genodermatoses.
MATERIALS AND METHODS
Cell lines and culture conditions
Human keratinocytes isolated from a newborn patient suffering
from the lethal, Herlitz-type JEB were kindly provided by Dr G.
Meneguzzi and have been described elsewhere (Dellambra et al.,
1998). These keratinocytes lack functional laminin 332 due to
the absence of the b3 chain of laminin 332 caused by a homozygous
premature stop codon in the LAMB3 gene. Primary H-JEB keratino-
cytes were immortalized using retrovirus-mediated transfer of the
HPV16 E6E7 encoding gene. Viruses were collected from PA317
LXSN 16E6E7 cells (ATCC no. CRL-2203). Primary NHKs and fibro-
blasts were isolated from the skin biopsy of healthy donors as
described previously (Nichols et al., 1977; Nickoloff et al., 1988). All
keratinocytes were cultured in Epilife culture media with supple-
ments and CaCl2 (Cascade Biologics, Portland, OR) on gelatinized
plates (BD Bioscience, Rockford, MA). Fibroblasts were cultured in
DMEM/F12 media supplemented with 15% fetal bovine serum
(Invitrogen, Carlsbad, CA).
Expression constructs
Full-length cDNA encoding human laminin b3 chain was obtained
from total RNA isolated from NHKs by reverse transcription-PCR
using GeneRacer core kit and LAMB3-specific primers: direct
50-ATGAGACCATTCTTCCTCTT-30 and reverse 50-CTTGCAGGTGG
CATAGTAGA-30. cDNA was subsequently inserted into the pcDNA
3.1 expression vector (Invitrogen). The integrity of the coding
sequence was verified by direct DNA sequencing using gene-
specific primers. The resulting plasmid was designated as pcDNA-
LAMB3.
Optimization of DNA delivery into 293F cells
Recombinant b3 chain was produced in 293F suspension cells
cultured in a FreeStyle Expression Medium (Invitrogen). Optimiza-
tion of DNA transfection into 293F cells was carried out using
293Fectin transfection reagent (Invitrogen) and Amaxa nucleofection
reaction (Amaxa Inc., Ko¨ln, Germany). A measure of 2 and 4 mg of
the pMaxGFP plasmid encoding green fluorescent protein (Amaxa
Inc.) was used for transfection and nucleofection, respectively.
Efficacy of the DNA delivery was estimated from green fluorescent
protein expression by fluorescent microscopy using AutoQuant
imaging software (AutoQuant Imaging Inc., Troy, NY).
Production and purification of the recombinant protein
For the medium-scale protein production, 80 nucleofection reac-
tions using 4mg of plasmid DNA and 1 106 293F cells per reaction
were set according to the Amaxa protocol. Nucleofected cells were
transferred into 200ml of culture media to obtain 4 105 cells per
ml and cultured for 24 hours. The volume of the media was then
doubled, and selectable agent (G418) was added to the media in
concentration 0.5mgml1. Each day for an additional 4 days the
volume of the culture media was doubled to obtain 3.2 l containing
1 106 protein-producing 293F cells per ml. The culture medium
was collected, clarified by centrifugation, concentrated 200 times on
Ultra-filtration Cell using YC-100 membrane (Millipore, Bedford,
MA), and dialyzed against gel filtration start buffer containing 0.05M
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Na2HPO4 and 0.15 M NaCl overnight in the presence of protease
inhibitors at þ 4 1C. Protein samples (4ml each, 4% of the gel
filtration column volume) were additionally purified by filtration and
fractionated on HiLoad 16/60 Superdex 200 prep grade gel filtration
column using fast performance liquid chromatography system
(GE Healthcare Bio-Sciences, Piscataway, NJ). Individual protein-
containing fractions were automatically collected based on the
absorption at 280 nm. Protein content of each individual fraction
was analyzed on SDS-PAGE. After multiple rounds of gel filtration,
all fractions containing b3 chains of laminin 332 were combined,
concentrated, and stored at þ 4 1C in the presence of 0.02% NaN3.
Recombinant protein was dialyzed against phosphate-buffered
saline (PBS) before the use.
Protein transfection in vitro
Normal and H-JEB keratinocytes (4 105 per well) were plated on a
six-well plate, and 48 hours later, when cells reached 70%
confluence, the cultures were used for the optimization of protein
delivery. Various amounts of b-galactosidase reporter protein (1, 2,
or 4 mg) were transfected into keratinocytes using ProJect protein
transfection reagent (Pierce, Rockford, IL). Intracellular presence of
the reporter protein was analyzed 12 hours after transfection using
standard b-galactosidase colorimetric activity assay. The efficacy of
the recombinant protein delivery was determined by counting
b-galactosidase-positive and -negative cells on five random high-
power fields (magnification  20) per transfection using AutoQuant
imaging software.
For the detection of the recombinant b3 delivery and secretion of
the restored laminin 332, H-JEB keratinocytes were transfected with
4mg of the recombinant protein under optimal conditions. Six hours
after transfection, protein-treated cells were harvested and re-plated
onto gelatinized tissue culture plates. After an additional 18 hours,
tissue culture media from the control and protein-transfected cells
were collected, cell debris was removed by centrifugation, and
clarified media were concentrated 100 times on YM-100 CentriPrep
concentrators (Millipore). Control and b3-transfected keratinocytes
were lysed in a buffer containing 1% sodium deoxycholate, 1%
Triton X-100, 0.1% SDS, 150mM NaCl, 50mM Tris–HCl (pH 7.4),
1.5mM EDTA, protease inhibitors, and 1mM PMSF (phenylmethyl-
sulfonyl fluoride). Protein concentration in media and cell lysates
was measured by Coomassie blue colorimetric assay (Pierce).
Samples for Western blot analysis were prepared under native and
denaturing conditions using corresponding sample buffers (Pierce).
Western blot analysis and immunoprecipitation
Native and denatured protein samples were separated on 4% (native
conditions) and 4–12% gradient (denaturing conditions) PAGE gels at
þ 4 1C and at room temperature, respectively. Proteins were
transferred onto polyvinylidene difluoride membranes. b3 polypep-
tide was detected using chain-specific mAbs raised against the
C-terminal amino acids (1–159) of the protein (anti-Kalinin B1, BD
Transduction Laboratories, San Jose, CA) in dilution 1:10,000.
Mature trimeric laminin 332 was detected using GB3 mAbs (Matsui
et al., 1995) in dilution 1:5,000. Immunocomplexes were detected
by horseradish peroxidase-labeled secondary antibodies and visua-
lized by WestFemto Supersignal detection kit (Pierce). To detect
incorporation of the recombinant b3 chain into trimeric laminin 332,
H-JEB keratinocytes (2 106) were transfected with recombinant b3
chain under optimal conditions. Twenty-four hours later, culture
medium (10ml) was collected, purified from cell debris, and
incubated with laminin 332-specific GB3 antibodies for 3 hours at
þ 4 1C with agitation. Immunocomplexes were precipitated with
Protein A sepharose (GE Healthcare Bio-Sciences), and protein
samples were prepared in denaturing conditions and separated on
4–12% SDS-PAGE. Individual chains of laminin 332 were detected
on blots using a3-, b3-, and g2-specific antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA; BD Transduction Laboratories, and
Chemicon International (Temecula, CA), respectively) as described
above.
Indirect immunofluorescent analysis
For indirect immunofluorescent microscopy, control and protein-
treated H-JEB keratinocytes were seeded onto gelatin-coated
chamber slides (Nalge Nunc, Rochester, NY) and cultured as indica-
ted in ‘‘Results’’. Prior to immunostaining, cells were fixed with
methanol at 20 1C and blocked with 1% BSA in Tris-buffered saline
for 1 hour at room temperature. Slides were incubated with b3- or
laminin 332-specific antibodies in a dilution 1:200 overnight at
þ 4 1C. For the co-detection of the endoplasmic reticulum, ERAB
antibodies (Santa Cruz Biotechnology) in dilution 1:200 were used.
Immunocomplexes were detected with AlexaFluor488- or Alexa-
Fluor594-conjugated secondary antibodies (Invitrogen). Slides were
then examined under light fluorescent microscope Nikon TS100F or
subjected to confocal fluorescent microscopy using Zeiss LSM 510
META. Confocal images were analyzed on the Zeiss LSM5 Image
Browser software (Carl Zeiss GmbH, Hamburg, Germany). For the
immunofluorescent detection of laminin b3 and laminin 332 on
cross-sections of human skin organotypic cultures, 7mm frozen
sections were fixed and processed as described above for cultured
cells.
Substrate binding assay
The binding strength of H-JEB cells to the plastic tissue culture
substrata after protein treatment was quantified using modified
McClay assay (McClay et al., 1981). Briefly, 6 hours after treatment
with recombinant protein, H-JEB keratinocytes were removed from
the plates by trypsinization and re-plated onto 96-well plates in
keratinocyte growth media at a density of 5 104 cells per well and
kept for 24 hours. Plates were centrifuge at 500 g at þ 4 1C for
20minutes. Cells adherent to the plastic substrata were fixed in 3%
formaldehyde and stained with 0.1% crystal violet. After washes,
plates were scanned at 570 nm on Bio Tech FL600 plate reader
(Biotech Inc., Richmond, VA). Results were obtained from three
independent experiments, three wells for each experiment.
Adhesion assay
To obtain ECM secreted by NHK, H-JEB, and protein-treated H-JEB,
cells were seeded at density of 3 105 cells per well into an
uncoated 96-well plate. Cells were cultured for 3 days under
standard tissue culture conditions. The adherent cells were then
removed by incubation in 0.05% trypsin–EDTA for 5minutes,
followed by two washes with trypsin inhibitor, incubation in 1%
Triton X-100 in PBS for 5minutes followed by overnight incubation
at þ 4 1C in PBS containing 20mM EDTA and protease inhibitors.
After incubation, detached cells were removed from the wells
by pipetting. The ECM was digested with 10 mgml1 DNase I for
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30minutes in 1% PBS. The wells were washed with PBS and used for
the assay. Untreated H-JEB keratinocytes were then plated onto
ECM-covered wells (5 105 cells per well) and incubated for
2 or 12 hours. Suspension cells were then removed by washing with
PBS. Adherent cells were fixed and stained with crystal violet, and
the absorbance was measured at 570 nm as described above.
Nonspecific background staining was evaluated on ECM-coated
plates. The value of background staining for each ECM was
subtracted from the value of staining in experimental wells. Results
were obtained from three independent experiments, three wells for
each experiment.
Organotypic human skin cultures
For dermal reconstruction, 1ml of a cell-free buffered collagen
solution consisting of bovine collagen type I (Organogenesis,
Canton, MA) at a final concentration of 0.8mgml1 in DMEM
containing 10% fetal calf serum, minimal essential medium with
Earle’s salts, 200mM L-glutamine, and 7.5% sodium bicarbonate was
added to tissue reconstruct inserts (Organogenesis). After hardening,
the precoated acellular layer was overlaid with 3ml of fibroblast-
containing collagen solution (2.4 104 cells per ml). After 7 days of
culturing, normal, H-JEB, or protein-transfected H-JEB keratinocytes
(5 105 cells per reconstruct) were seeded on top of the contracted
collagen gels. Reconstructs were cultured in complete keratinocyte
culture medium (Cascade Biologics) with the addition of 1 ngml1 of
human recombinant EGF for 2 days. The media were then replaced
with the one containing reduced amount of EGF (0.2 ngml1), and
cells were cultured for additional 2 days. After that, the medium was
replaced with a fresh one containing increased CaCl2 concentration
(0.5mM) without EGF. At this point, skin reconstructs were lifted to
the air–liquid interface, and, unless otherwise stated, were main-
tained for additional 14 days with feeding from the bottom of the
insert. Reconstructs were then harvested and embedded into OCT
(optical cutting temperature) compound for cryosectioning and
analysis.
Fluorescence imaging and analysis
For the analysis of laminin 332 distribution and quantitation, 50
consecutive cross-sections of the reconstructs comprised of normal,
H-JEB, or b3-treated H-JEB keratinocytes were stained with GB3
antibodies and AlexaFluor488-labeled secondary antibodies. Images
of stained cross-sections were taken and analyzed using AutoQuant
imaging software (AutoQuant Imaging Inc.). For the analysis of
distribution, all fluorescence-positive regions associated with the
BMZ were automatically detected on each image. Consecutive
images were merged into a three-dimensional composite. Fluores-
cence-positive regions associated with the BMZ were detected, and
intensity of fluorescence was measured on each image using
AutoQuant imaging software. Gaps between fluorescence-positive
regions of the BMZ were manually outlined, and areas of the gaps
were calculated using imaging software. Average value of the BMZ-
associated fluorescence collected from 50 consecutive images was
calculated. The average value of total fluorescence on 50 images of
normal skin reconstruct was designated as 100%, and percentage of
the BMZ-associated fluorescence in normal, H-JEB, or b3-treated
H-JEB skin reconstructs was calculated. Proteins on cryosections were
detected using anti-laminin 332, anti-b3, anti-integrin a6 (Millipore),
and anti-integrin b4 (Santa Cruz Biotechnology) antibodies.
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